Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The field of in vivo gene therapy has matured to the point where there are numerous clinical trials underway including late-stage clinical trials. Several viral vectors are especially efficient and support lifetime protein expression in the brain and a number of clinical trials are underway for various progressive or chronic neurological disorders including Parkinson's disease, Alzheimer's disease, and Batten's disease. To date, however, none of the vectors in clinical use have any direct way to reverse or control their transgene product in the event continued protein expression should become problematic. Several schemes that use elements within the vector design have been developed that allow an external drug or pro-drug to alter ongoing protein expression after in vivo gene transfer. The most promising and most studied regulated protein expression methods for in vivo gene transfer are reviewed. In addition, potential scientific and clinical advantages of transgene regulation for gene therapy are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Neural substrates of awakening probed with optogenetic control of hypocretin neurons
Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K., & de Lecea, L. (2007) · Nature · doi:10.1038/nature06310 · Cited by 1,341
Banaszynski, L. A., Chen, L.-C., Maynard-Smith, L. A., Ooi, A. G. L., & Wandless, T. J. (2006) · Cell · doi:10.1016/j.cell.2006.07.025 · Cited by 902
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
An optogenetic toolbox designed for primates
Diester, I., Kaufman, M. T., Mogri, M., Pashaie, R., Goo, W., Yizhar, O., Ramakrishnan, C., Deisseroth, K., & Shenoy, K. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2749 · Cited by 443
Improved Tet-responsive promoters with minimized background expression
Loew, R., Heinz, N., Hampf, M., Bujard, H., & Gossen, M. (2010) · BMC Biotechnology · doi:10.1186/1472-6750-10-81 · Cited by 246
A genomic screen for activators of the antioxidant response element
Liu, Y., Kern, J. T., Walker, J. R., Johnson, J. A., Schultz, P. G., & Luesch, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700898104 · Cited by 196
Latta-Mahieu, M., Rolland, M., Caillet, C., Wang, M., Kennel, P., Mahfouz, I., Loquet, I., Dedieu, J.-F., Mahfoudi, A., Trannoy, E., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340260201707 · Cited by 114
AAV9: a potential blood-brain barrier buster
Manfredsson, F. P., Rising, A. C., & Mandel, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.15 · Cited by 94
Self-citationBlasey, C. M., DeBattista, C., Roe, R., Block, T., & Belanoff, J. K. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.03.001 · Cited by 61
Research works printed but not linked: 76
- Auslander, 2010, A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression, Mol. Biosyst., 6, 807, 10.1039/b923076a · DOI
- Banaszynski, 2008, Chemical control of protein stability and function in living mice, Nat. Med., 14, 1123, 10.1038/nm.1754 · DOI · Paper page
- Barza, 1975, Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs, Antimicrob. Agents Chemother., 8, 713, 10.1128/AAC.8.6.713 · DOI · Paper page
- Bass, 2010, Optogenetic control of striatal dopamine release in rats, J. Neurochem., 114, 1344, 10.1111/j.1471-4159.2010.06850.x · DOI · Paper page
- Benzekhroufa, 2009, Targeting central serotonergic neurons with lentiviral vectors based on a transcriptional amplification strategy, Gene Ther., 16, 681, 10.1038/gt.2009.7 · DOI
- Berman, 2007, Update on rosacea and anti-inflammatory-dose doxycycline, Drugs Today (Barc.), 43, 27, 10.1358/dot.2007.43.1.1025697 · DOI
- Blasey, 2011, Efficacy and safety of mifepristone for the treatment of psychotic depression, J. Clin. Psychopharmacol., 31, 436, 10.1097/JCP.0b013e3182239191 · DOI · Paper page
- Burcin, 1999, Adenovirus-mediated regulable target gene expression in vivo, Proc. Natl. Acad. Sci. U. S. A., 96, 355, 10.1073/pnas.96.2.355 · DOI · Paper page
- Cao, 2009, Molecular therapy of obesity and diabetes by a physiological autoregulatory approach, Nat. Med., 15, 447, 10.1038/nm.1933 · DOI · Paper page
- Caron, 2005, The Lac repressor provides a reversible gene expression system in undifferentiated and differentiated embryonic stem cell, Cell. Mol. Life Sci., 62, 1605, 10.1007/s00018-005-5123-2 · DOI
- Chang, 2008, Molecular, cellular, and behavioral characterization of a tetracycline (Tet)-regulated rAAV vector for human aromatic amino acid decarboxylase (hAADC) in a rat model of Parkinson's disease (PD), Mol. Ther., 16, S264, 10.1016/S1525-0016(16)40109-7 · doi:10.1016/s1525-0016(16)40109-7
- Chojnacki, 2009, Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both?, Nat. Rev. Neurosci., 10, 153, 10.1038/nrn2571 · DOI · Paper page
- Christopherson, 1992, Ecdysteroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone receptor and chimeric transactivators, Proc. Natl. Acad. Sci. U. S. A., 89, 6314, 10.1073/pnas.89.14.6314 · DOI · Paper page
- Chtarto, 2003, Tetracycline-inducible transgene expression mediated by a single AAV vector, Gene Ther., 10, 84, 10.1038/sj.gt.3301838 · DOI · Paper page
- Chtarto, 2007, Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector, Exp. Neurol., 204, 387, 10.1016/j.expneurol.2006.11.014 · DOI
- Cronin, 2001, The lac operator–repressor system is functional in the mouse, Genes Dev., 15, 1506, 10.1101/gad.892001 · DOI · Paper page
- Culler, 2010, Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins, Science, 330, 1251, 10.1126/science.1192128 · DOI · Paper page
- Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 · DOI · Paper page
- Fiala, 2010, Optogenetic approaches in neuroscience, Curr. Biol., 20, R897, 10.1016/j.cub.2010.08.053 · DOI
- Forsayeth, 2011, AAV9: over the fence and into the woods, Mol. Ther., 19, 1006, 10.1038/mt.2011.95 · DOI · Paper page
- Georgievska, 2004, Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector, Hum. Gene Ther., 15, 934, 10.1089/hum.2004.15.934 · DOI · Paper page
- Golde, 2011, Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift, Neuron, 69, 203, 10.1016/j.neuron.2011.01.002 · DOI · Paper page
- Gordon, 1996, Detection of herpes simplex virus (types 1 and 2) and human herpesvirus 6 DNA in human brain tissue by polymerase chain reaction, Clin. Diagn. Virol., 6, 33, 10.1016/0928-0197(95)00203-0 · DOI
- Gross, 2009, Mifepristone treatment of olanzapine-induced weight gain in healthy men, Adv. Ther., 26, 959, 10.1007/s12325-009-0070-1 · DOI
- Haberman, 2002, Regulation of gene expression in adeno-associated virus vectors in the brain, Methods, 28, 219, 10.1016/S1046-2023(02)00226-8 · DOI
- Hadaczek, 2011, Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system, PLoS One, 6, e27728, 10.1371/journal.pone.0027728 · DOI · Paper page
- Ho, 1996, Dimeric ligands define a role for transcriptional activation domains in reinitiation, Nature, 382, 822, 10.1038/382822a0 · DOI · Paper page
- Hou, 2007, A novel adenoviral vector-mediated neuronal selective gene expression in neonatal mouse brain in response to hypoxia, Neurosci. Lett., 419, 23, 10.1016/j.neulet.2007.03.059 · doi:10.1016/j.neulet.2007.03.059
- Hu, 1987, The inducible lac operator–repressor system is functional in mammalian cells, Cell, 48, 555, 10.1016/0092-8674(87)90234-0 · DOI · Paper page
- Hurttila, 2008, Oxidative stress-inducible lentiviral vectors for gene therapy, Gene Ther., 15, 1271, 10.1038/gt.2008.75 · DOI
- Hwang, 2001, A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons, Hum. Gene Ther., 12, 1731, 10.1089/104303401750476230 · DOI · Paper page
- Iwamoto, 2010, A general chemical method to regulate protein stability in the mammalian central nervous system, Chem. Biol., 17, 981, 10.1016/j.chembiol.2010.07.009 · DOI · Paper page
- Jakobsson, 2003, Targeted transgene expression in rat brain using lentiviral vectors, J. Neurosci. Res., 73, 876, 10.1002/jnr.10719 · DOI · Paper page
- Jakobsson, 2004, Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector, Eur. J. Neurosci., 19, 761, 10.1111/j.0953-816X.2003.03147.x · DOI · Paper page
- Karatas, 2008, Investigation of HSV-1, HSV-2, CMV, HHV-6 and HHV-8 DNA by real-time PCR in surgical resection materials of epilepsy patients with mesial temporal lobe sclerosis, J. Neurol. Sci., 264, 151, 10.1016/j.jns.2007.08.010 · DOI
- Lamartina, 2003, Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates, Mol. Ther., 7, 271, 10.1016/S1525-0016(02)00051-5 · DOI · Paper page
- Lewin, 2001, Ribozyme gene therapy: applications for molecular medicine, Trends Mol. Med., 7, 221, 10.1016/S1471-4914(01)01965-7 · DOI
- Liu, 1997, Identification of cell type-specific promoter elements associated with the rat tyrosine hydroxylase gene using transgenic founder analysis, Brain Res. Mol. Brain Res., 50, 33, 10.1016/S0169-328X(97)00163-0 · DOI
- Liu, 2008, Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea, Mol. Ther., 16, 474, 10.1038/sj.mt.6300379 · DOI
- Lonergan, 2005, Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression, Physiol. Genomics, 20, 165, 10.1152/physiolgenomics.00120.2004 · DOI
- Lowenstein, 2007, Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions, Curr. Gene Ther., 7, 347, 10.2174/156652307782151498 · DOI · Paper page
- Mandel, 2006, Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders, Mol. Ther., 13, 463, 10.1016/j.ymthe.2005.11.009 · DOI · Paper page
- Manfredsson, 2009, Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector, Mol. Ther., 17, 1857, 10.1038/mt.2009.196 · DOI · Paper page
- Manfredsson, 2009, Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease, Curr. Gene Ther., 9, 375, 10.2174/156652309789753400 · DOI
- Manfredsson, 2009, Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity, Mol. Ther., 17, 980, 10.1038/mt.2009.45 · DOI · Paper page
- Mansuy, 2000, Tetracycline-regulated gene expression in the brain, Curr. Opin. Neurobiol., 10, 593, 10.1016/S0959-4388(00)00127-6 · DOI
- Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol., 9, 1164, 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
- Min, 1994, 5′ Upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice, Brain Res. Mol. Brain Res., 27, 281, 10.1016/0169-328X(94)90011-6 · DOI
- No, 1996, Ecdysone-inducible gene expression in mammalian cells and transgenic mice, Proc. Natl. Acad. Sci. U. S. A., 93, 3346, 10.1073/pnas.93.8.3346 · DOI · Paper page
- Nordstrom, 2003, The antiprogestin-dependent GeneSwitch system for regulated gene therapy, Steroids, 68, 1085, 10.1016/j.steroids.2003.07.008 · DOI
- Oh, 2009, Expression of transgenes in midbrain dopamine neurons using the tyrosine hydroxylase promoter, Gene Ther., 16, 437, 10.1038/gt.2008.148 · DOI · Paper page
- Oligino, 1998, Drug inducible transgene expression in brain using a herpes simplex virus vector, Gene Ther., 5, 491, 10.1038/sj.gt.3300612 · DOI
- Peel, 1997, Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters, Gene Ther., 4, 16, 10.1038/sj.gt.3300358 · DOI · Paper page
- Pollock, 2000, Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector, Proc. Natl. Acad. Sci. U. S. A., 97, 13221, 10.1073/pnas.230446297 · DOI
- Rivera, 1996, A humanized system for pharmacologic control of gene expression, Nat. Med., 2, 1028, 10.1038/nm0996-1028 · DOI · Paper page
- Rivera, 2000, Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum, Science, 287, 826, 10.1126/science.287.5454.826 · DOI · Paper page
- Rock, 1983, Detection of HSV-1 genome in central nervous system of latently infected mice, Nature, 302, 523, 10.1038/302523a0 · DOI · Paper page
- Shen, 2006, Adeno-associated viral-vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice, Stroke, 37, 2601, 10.1161/01.STR.0000240407.14765.e8 · DOI · Paper page
- Suess, 2003, Conditional gene expression by controlling translation with tetracycline-binding aptamers, Nucleic Acids Res., 31, 1853, 10.1093/nar/gkg285 · DOI
- Svedhem, 1979, Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment, J. Antimicrob. Chemother., 5, 717, 10.1093/jac/5.6.717 · doi:10.1093/jac/5.6.717
- Szulc, 2008, Conditional gene expression and knockdown using lentivirus vectors encoding shRNA, Methods Mol. Biol., 434, 291
- Szymanski, 2006, Development and characterization of a synthetic promoter for selective expression in proliferating endothelial cells, J. Gene Med., 8, 514, 10.1002/jgm.875 · doi:10.1002/jgm.875
- Szymanski, 2007, Development and validation of a robust and versatile one-plasmid regulated gene expression system, Mol. Ther., 15, 1340, 10.1038/sj.mt.6300171 · DOI
- Tang, 2002, Vigilant vectors: adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases, Methods, 28, 259, 10.1016/S1046-2023(02)00231-1 · DOI
- Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121 · DOI · Paper page
- Vaillancourt, 2003, Retroviral delivery of the ecdysone-regulatable gene expression system, Biotechnol. Prog., 19, 1750, 10.1021/bp0341085 · doi:10.1021/bp0341085
- Wang, 1994, A regulatory system for use in gene transfer, Proc. Natl. Acad. Sci. U. S. A., 91, 8180, 10.1073/pnas.91.17.8180 · DOI · Paper page
- Warren, 1977, Isolation of Herpes simplex virus from human trigeminal ganglia, including ganglia from one patient with multiple sclerosis, Lancet, 2, 637, 10.1016/S0140-6736(77)92501-6 · doi:10.1016/s0140-6736(77)92501-6
- Williams, 2001, Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas, Mol. Ther., 4, 593, 10.1006/mthe.2001.0499 · DOI
- Xie, 2008, A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types, Toxicol. In Vitro, 22, 261, 10.1016/j.tiv.2007.08.019 · DOI
- Xie, 2011, MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression, Mol. Ther., 19, 526, 10.1038/mt.2010.279 · DOI · Paper page
- Xiong, 2008, Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain, Mol. Ther., 16, 343, 10.1038/sj.mt.6300375 · DOI
- Xu, 2006, Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States, JAMA, 296, 964, 10.1001/jama.296.8.964 · DOI · Paper page
- Yang, 2009, Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model, J. Gene Med., 11, 899, 10.1002/jgm.1377 · DOI
- Ye, 1999, Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer, Science, 283, 88, 10.1126/science.283.5398.88 · DOI · Paper page
- Yen, 2004, Exogenous control of mammalian gene expression through modulation of RNA self-cleavage, Nature, 431, 471, 10.1038/nature02844 · DOI · Paper page
Cited by
Tet-On Systems For Doxycycline-inducible Gene Expression
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160524144041 · Cited by 434
“Because adverse effects of uncontrolled delivery of neurotrophic factors have been described [22-24], the ability to modulate transgene expression is crucial for these applications [25, 26].”
BackgroundImmunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105
Cardenas-Aguayo, M. D. C., Kazim, S. F., Grundke-Iqbal, I., & Iqbal, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053596 · Cited by 73
“However, this approach is now in evaluation, and it requires additional improvements to guarantee the safety of the patients [32,33].”
BackgroundPromising therapeutic agents for the treatment of Parkinson’s disease
Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1164687 · Cited by 7
Metadata
- Authors
- Manfredsson, F. P., Bloom, D. C., & Mandel, R. J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 48
- Issue
- 2
- Pages
- 212-221
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2042759985
- Cited by
- 29
- References
- 14
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.